Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoTD: GVHD Prophylaxis Following Unrelated Donor Stem Cell Transplantation
NCT04888741Phase 2Recruiting
- Sponsor
- University of Birmingham
- Start
- Feb 2021
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by University of Birmingham. Started Feb 2021; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04888741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888741.